JOSÉ LUIS PABLOS ÁLVAREZ-rekin lankidetzan egindako argitalpenak (18)

2020

  1. Comparative Study of Senescent Th Biomarkers in Healthy Donors and Early Arthritis Patients. Analysis of VPAC Receptors and Their Influence

    Cells, Vol. 9, Núm. 12

2018

  1. Inhibitory role of growth hormone in the induction and progression phases of collagen-induced arthritis

    Frontiers in Immunology, Vol. 9, Núm. MAY

  2. Methotrexate limits inflammation through an A20-dependent cross-tolerance mechanism

    Annals of the Rheumatic Diseases, Vol. 77, Núm. 5, pp. 752-759

2014

  1. VIP modulates IL-22R1 expression and prevents the contribution of rheumatoid synovial fibroblasts to IL-22-mediated joint destruction

    Journal of Molecular Neuroscience, Vol. 52, Núm. 1, pp. 10-17

2013

  1. IL-22/IL-22R1 axis and S100A8/A9 alarmins in human osteoarthritic and rheumatoid arthritis synovial fibroblasts

    Rheumatology (United Kingdom), Vol. 52, Núm. 12, pp. 2177-2186

  2. Inflammatory mediators alter interleukin-17 receptor, interleukin-12 and -23 expression in human osteoarthritic and rheumatoid arthritis synovial fibroblasts: Immunomodulation by vasoactive intestinal peptide

    NeuroImmunoModulation, Vol. 20, Núm. 5, pp. 274-284

2011

  1. CXCL12 gene expression is upregulated by hypoxia and growth arrest but not by inflammatory cytokines in rheumatoid synovial fibroblasts

    Cytokine, Vol. 53, Núm. 2, pp. 184-190

  2. Mapping the CRF-urocortins system in human osteoarthritic and rheumatoid synovial fibroblasts: Effect of vasoactive intestinal peptide

    Journal of Cellular Physiology, Vol. 226, Núm. 12, pp. 3261-3269

  3. RNA sensors in human osteoarthritis and rheumatoid arthritis synovial fibroblasts: Immune regulation by vasoactive intestinal peptide

    Arthritis and Rheumatism, Vol. 63, Núm. 6, pp. 1626-1636

2008

  1. Differential expression of vasoactive intestinal peptide and its functional receptors in human osteoarthritic and rheumatoid synovial fibroblasts

    Arthritis and Rheumatism, Vol. 58, Núm. 4, pp. 1086-1095

  2. Immunoregulatory properties of vasoactive intestinal peptide in human T cell subsets: Implications for rheumatoid arthritis

    Brain, Behavior, and Immunity, Vol. 22, Núm. 3, pp. 312-317

  3. VIP reverses the expression profiling of TLR4-stimulated signaling pathway in rheumatoid arthritis synovial fibroblasts

    Molecular Immunology, Vol. 45, Núm. 11, pp. 3065-3073

2006

  1. CXCL12 is displayed by rheumatoid endothelial cells through its basic amino-terminal motif on heparan sulfate proteoglycans

    Arthritis Research and Therapy, Vol. 8, Núm. 2

  2. VIP decreases TLR4 expression induced by LPS and TNF-α treatment in human synovial fibroblasts

    Annals of the New York Academy of Sciences

  3. VIP down-regulates TLR4 expression and TLR4-mediated chemokine production in human rheumatoid synovial fibroblasts

    Rheumatology, Vol. 45, Núm. 5, pp. 527-532

2005

  1. Coexpression of AT1 and AT2 receptors by human fibroblasts is associated with resistance to angiotensin II

    Peptides, Vol. 26, Núm. 9, pp. 1647-1653

  2. Topical application of a peptide inhibitor of transforming growth factor-β1 ameliorates bleomycin-induced skin fibrosis

    Journal of Investigative Dermatology, Vol. 125, Núm. 3, pp. 450-455

2004

  1. Vasoactive intestinal peptide modulates proinflammatory mediator synthesis in osteoarthritic and rheumatoid synovial cells

    Rheumatology, Vol. 43, Núm. 4, pp. 416-422